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Abstract: Dilated cardiomyopathy (DCM) is one of the leading causes of heart failure and heart
transplantation. A portion of familial DCM is due to mutations in the LMNA gene encoding the
nuclear lamina proteins lamin A and C and without adequate treatment these patients have a poor
prognosis. To get better insights into pathobiology behind this disease, we focused on modeling
LMNA-related DCM using human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CM).
Primary skin fibroblasts from DCM patients carrying the most prevalent Finnish founder mutation
(p.S143P) in LMNA were reprogrammed into hiPSCs and further differentiated into cardiomyocytes
(CMs). The cellular structure, functionality as well as gene and protein expression were assessed in
detail. While mutant hiPSC-CMs presented virtually normal sarcomere structure under normoxia,
dramatic sarcomere damage and an increased sensitivity to cellular stress was observed after hypoxia.
A detailed electrophysiological evaluation revealed bradyarrhythmia and increased occurrence of
arrhythmias in mutant hiPSC-CMs on β-adrenergic stimulation. Mutant hiPSC-CMs also showed
increased sensitivity to hypoxia on microelectrode array and altered Ca2+ dynamics. Taken together,
p.S143P hiPSC-CM model mimics hallmarks of LMNA-related DCM and provides a useful tool to
study the underlying cellular mechanisms of accelerated cardiac degeneration in this disease.
Keywords: dilated cardiomyopathy; LMNA; Lamin A/C; induced pluripotent stem cell; hypoxia;
microelectrode array and calcium imaging
1. Introduction
Dilated cardiomyopathy (DCM) is a cardiac disorder characterized by weakening of the heart
muscle due to a progressive loss of functional cardiomyocytes, dilation of cardiac ventricles, reduced
cardiac output and arrhythmias [1]. Of all cases 25–30% are hereditary with an estimated incidence of
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1:250–2500 [2,3]. Mutations in more than 30 different genes have been linked to the genetic form of DCM
and the second most commonly mutated gene is LMNA, encoding nuclear lamin A and C proteins [3–5].
Lamins play an essential role in determining nuclear size, shape, stiffness and they have also been
implicated in cell cycle progression, chromatin organization and DNA damage response [6]. A-type
lamins, primarily lamin A and C, are derived through alternative splicing of the LMNA gene while
B-type lamins (lamin B1 and B2) are encoded by two distinct genes, LMNB1 and LMNB2, respectively.
Over 500 mutations identified in the LMNA gene (http://www.umd.be/LMNA/) cause an exceptional
variety of diseases commonly called laminopathies. In addition to DCM, these include e.g., muscular
dystrophies, lipodystrophies, peripheral neuropathy and premature aging (progeria) [7], many of
which also exhibit some features of cardiac disease.
A significant number of patients with LMNA mutations display complications only in the
cardiovascular system and many remain undiagnosed [8]. Clinically, DCM patients and their family
members carrying LMNA mutations should be identified for several reasons. First, the penetrance
of the disease is nearly 100% among mutation carriers. Secondly, the cardiac dysfunction is almost
always preceded by the conduction system disease, such as atrioventricular block, atrial fibrillation
and sometimes potentially fatal ventricular arrhythmias or asystole [9]. Such patients with LMNA
mutations are at a significantly higher risk of sudden death compared to other forms of DCM [10].
92% of patients carrying LMNA gene mutations with either cardiac or neuromuscular phenotype
were reported to present cardiac arrhythmias after the age of 30, 64% developed heart failure after the
age of 50 and sudden death was the most common cause of death (46%) [11]. The current medical
treatment includes general heart failure management with β-blockers and ACE inhibitors, but the
existing therapy of DCM is not optimal [12,13]. Therefore, also intensively followed DCM patients
with LMNA mutations have a poor prognosis and an intervention with a pacemaker or an implantable
defibrillator, as well as cardiac transplantation, is occasionally needed [9].
The detailed mechanisms by which mutations in nuclear lamins cause DCM and cardiac
dysfunction are still poorly understood but accumulating data from patients and animal models
suggest that alterations in lamina structure initiate the onset of the disease by defective electrical
signaling and molecular response to mechanical stress. Additionally, the mutations cause changes
in chromatin organization and gene activity leading to altered gene expression and signaling and to
progressive weakening of cardiac muscle; for review see [12,14].
Several mouse models have been established to study the pathophysiology of LMNA-related
DCM [13,15–17]. Although important knowledge has been gained with the existing mouse models,
generation of human induced pluripotent stem cells (hiPSC) provides an exceptional opportunity
to make patient-specific cardiomyocytes (CMs) and study the underlying mechanism of DCM with
human cardiac cells in vitro as reported in a hiPSC model for LMNA-related DCM model [18].
In accordance with the LmnaH222P/H222P mouse model work [15], Siu et al. showed that MAPK
inhibitors (U0126 and selumetinib) alleviate nuclear defects and apoptosis after electrical stimulation in
hiPSC-CMs carrying the LMNAR225X/WT mutation. In another study, application of Ataluren (PTC124)
protected LMNAR225X/WT hiPSC-CMs but not LMNAQ354X/WT or LMNAT518fs/WT hiPSC-CMs from
nuclear abnormalities and apoptosis [19]. Ataluren also improved the excitation–contraction coupling
and contractile functions in LMNAR225X/WT hiPSC-CMs [19]. These studies emphasize the importance of
personalized medicine for DCM treatment. In addition to DCM, hiPSC-CMs have been successfully used
to model several other cardiac diseases e.g., hypertrophic cardiomyopathy [20], arrhythmogenic right
ventricular cardiomyopathy [21] and long QT-syndrome [22]. Although iPSCs-CMs are a promising
tool for disease modeling and drug discovery, the yield of mature cardiomyocytes, tumorigenic
potential of the reprogrammed cells and the immune response of potential recipient require more
research before any clinical applications [23].
In Finland, a heterozygous founder mutation p.S143P in LMNA is the most prevalent
DCM-associated mutation with typical clinical phenotype [24]. We have previously shown that
p.S143P mutation increases lamin A/C nucleoplasmicity, mobility and tendency to form intranuclear
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aggregates in patient fibroblasts and further activates unfolded protein response (UPR) [25]. In this
follow-up work, hiPSC-CMs were generated from two individuals carrying the p.S143P LMNA
mutation and the cellular structure, electrophysiological features and sensitivity to physiological stress
(i.e., hypoxia) were compared to CMs from two healthy control individuals.
2. Materials and Methods
2.1. Patient Characteristics
Biopsies from two healthy controls and two patients carrying the p.S143P mutation in the
LMNA [22,25] were used for this study. Healthy control cells were derived from a 55-year-old
female (UTA.04602.WT) and from a 30-year-old male (UTA.11505.WT). Mutation carrier 1 (DCM1,
UTA.12704.LMNA) is a 24-year-old male and mutation carrier 2 (DCM2, UTA.12619.LMNA) a
34-year-old female. DCM1 presented a high number of ventricular extrasystoles (9%) and one
non-sustained ventricular-tachycardia (VT) period of 15 beats in ECG (electrocardiogram). His ejection
fraction and serum brain natriuretic peptide levels were normal. DCM2 had a first-degree
atrio-ventricular (AV) block and paroxysmal atrial flutter. Her ejection fraction was 41% at the
lowest, but usually within the normal range. Both patients were on β-blocker therapy and had a family
history of heart transplantation due to LMNA mutation. A signed informed consent was obtained
from all the individuals participating in the study. The study was approved by the Ethics Committee
of the Pirkanmaa Hospital District to establish, culture and differentiate hiPSC lines (R08070).
2.2. hiPSC Generation, Culture and Characterization
Two control and two DCM hiPSC lines were generated. Derivation of one control line
(UTA.04602.WT) had been reprogrammed by lentiviral infection and characterized previously [22,26].
The second control UTA.11505.WT and two patient lines UTA.12704.LMNA and UTA.12619.LMNA
were generated by sendai virus infection and all the lines were characterized similar to the control line
UTA.04602.WT. Two control and two mutant cell lines were used throughout the study. However, due to
lower differentiation efficiency of control2 line, the data from control1 and control2 was combined,
unless otherwise indicated.
2.3. Cardiomyocyte Differentiation
hiPSCs were differentiated into cardiomyocytes as described earlier [27] using KO-DMEM (GIBCO,
Invitrogen, Carlsbad, CA, USA) supplemented with CHIR99201 and IWP (inhibitor of WNT pathway)
in B27 (GIBCO). This method yielded beating cardiac cultures within 8–10 days. All cardiac cells were
maintained in KO-DMEM supplemented with 20% FBS and let to mature for at least 30 days before
dissociation and use in experiments.
2.4. Genotyping
DNA sequencing was performed to confirm the presence of the p.S143P mutation in the
patient-derived hiPSCs lines. Genomic DNA was extracted from hiPSC lines (Macherey Nagel DNA,
RNA protein purification NucleoSpin Tissue XS kit, Düren, Germany). A PCR fragment of 776 bp
around the LMNA mutation was amplified using polymerase chain reaction (PCR). The PCR was
done using forward Primer LMNA_Fwd-GGCTCAGATCGAGAAGTGCTAGGGA, and reverse Primer
LMNA_Rev-ATGACTCTAGGACAGGTGAATGGCTCTG at conditions 95 ◦C 2.30 min, then 30 cycles
(95 ◦C, 0.30 min; 59 ◦C, 0.30 min; 72 ◦C, 0.50 min), a final extension at 72 ◦C 10 min and 4 ◦C cooling. The
PCR product (776 bp) was electrophoresed on a 1% agarose gel and purified (NucleoSpin Gel and PCR
Clean up Kit from Macherey-Nagel, Düren, Germany). Sequencing was carried out with the same forward
primer. The product was then sent for sequencing at the Tampere facility of NGS and Sanger Sequencing.
In order to verify that the LMNA mutation is transcribed in the hiPSC-CMs, we carried out a
qRT-PCR with mutation and wild type specific primers. One µg of RNA was converted to cDNA using
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a SensiFAST cDNA Synthesis kit (Bioline, London, UK). The amplification step was performed using a
SensiFAST SYBR Lo-ROX qPCR kit (Bioline) according to the manufacturer’s protocol as follows: 3 min
at 95 ◦C followed by 40 cycles of 5 s at 95 ◦C, 10 s at 60 ◦C and 15 s at 72 ◦C. Target genes were normalized
to GAPDH expression and the values were calculated using the 2−∆∆Ct method. The primers used
were for GAPDH 5′-TAAATTGAGCCCGCAGCCTCCC-3’ and 5′-ATGTGGCTCGGCTGGCGACG-3’;
LMNA TOTAL 5’-GGGATGCCCGCAAGACCCTT-3’ and 5’-GGTATTGCGCGCTTTCAGCTCC-3’;
LMNA WT 5’-GCTCTGCTGAACTCCAAGGAGG-3’ and 5’-GCCTCAAGCTTGGCCACCTG-3’; LMNA
S143P 5’-GCTCTGCTGAACCCCAAGGAGG-3’ and 5’-GCCTCAAGCTTGGCCACCTG-3’.
2.5. Immunofluorescence and Confocal Microscopy
Dissociated CMs were fixed in 10% formalin for 10 min and permeabilized with 0.1% Triton X-100
for 10 min. For the ischemic stress (hypoxia and serum/glucose deprivation) induction, CMs were
washed twice with 1× PBS and transferred in 1% O2 in a hypoxic workstation (Invivo2 400, Ruskinn
Technology, Bridgend, UK) with oxygen replaced by 99.5% pure N2 (AGA, Espoo, Finland). Degassed
serum and glucose deficient medium was changed inside the hypoxic workstation. After hypoxia
(2–5 h) cells were washed twice with degassed 1× PBS and fixed inside the workstation.
The primary antibodies used were goat monoclonal Troponin T (cTnT, 1:2500, ab64623, Abcam,
Cambridge, UK), mouse α-actinin (1:800, A7811, Sigma-Aldrich, Saint Louis, MO, USA), rabbit polyclonal
lamin A (1:1000, 323-10, kindly provided by prof. Robert D. Goldman, Northwestern University,
USA) and mouse monoclonal hypoxia-inducible factor 1-α (Hif-1α, 1:1000, clone-54, BD Biosciences,
Franklin, NJ, USA). The secondary antibodies were donkey anti-rabbit IgG conjugated to Alexa Fluor
488, donkey anti-mouse IgG conjugated to Alexa Fluor 555 and goat anti-chicken IgG conjugated to
Alexa Fluor 647 (all Molecular Probes, Eugene, OR, USA). ProLong Diamond Antifade Mountant with
DAPI was used to visualize DNA (Thermo Fisher Scientific, Waltham, MA, USA).
The spinning disk confocal microscope used was a 3i Marianas with Yokogawa CSU-W1 scanning
unit on an inverted Zeiss AxioObserver Z1 microscope, controlled by SlideBook 6 software (Intelligent
Imaging Innovations GmbH, Göttingen, Germany). The objective used was 63×/1.4 oil. Images were
acquired with ORCA Flash4 sCMOS camera (Hamamatsu Photonics, Hamamatsu, Japan) and analyzed
with BioImageXD [28] and ImageJ Fiji software [29]. 20 to 30 nuclei were randomly selected and the
mean area, circularity and fluorescence intensities of lamin A within the lamina (L) and nucleoplasmic
(N) regions were quantified with ImageJ Fiji. The ratio of fluorescence between the lamina and
nucleoplasma were calculated as follows:
intensity ratio =
(N− B)
(L− B) ,
where B is the background. The sarcomere length and organization analysis was done with ImageJ
plugin TTorg as previously descripted [30]. A two sample t-test was used to analyze the differences
between control and DCM-CMs in nucleoplasmicity, sarcomere length and organization. p < 0.05 was
considered statistically significant.
2.6. Transmission Electron Microscopy
Dissociated CMs were fixed with 5% glutaraldehyde in 0.16 M s-collidine buffer, pH 7.4, post fixed
with 2% OsO4 containing 3% potassium ferrocyanide for 2 h, dehydrated with different ethanol
concentrations (70%, 96%, 2 × 100%) and embedded with a 45359 Fluka Epoxy Embedding Medium
kit. 70 nm sections were cut with an ultramicrotome and stained with 1% uranyl acetate and 0.3% lead
citrate. The images were acquired with a JEOL JEM-1400 Plus TEM (Tokyo, Japan) equipped with a
OSIS Quemesa 11 Mpix bottom-mounted digital camera operated at 80 kV acceleration voltage.
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2.7. Immunoblotting
CMs were lysed in a M-PER mammalian protein extraction reagent (Thermo Fisher Scientific)
complemented with 1× protease and 1× phosphatase inhibitors. Hypoxia-treated cells were lysed inside
the hypoxia workstation. Protein concentration was measured using Pierce Coomassie Plus Protein
Assay kit (Thermo Fisher Scientific). Cell lysates were mixed with 2× SDS-PAGE sample buffer and 15µg
of protein lysate was run on a 4–10% gradient gel (BioRad, Hercules, CA, USA). The primary antibodies
used were mouse monoclonal anti-actin (1:1000, AC-40, Sigma-Aldrich), mouse monoclonal lamin A/C
(LAC, 1:10,000, 5G4, kindly provided by Prof. Robert D. Goldman, Northwestern University, USA),
mouse monoclonal heat shock protein 90 (Hsp90, 1:2000, ADI-SPA-830, Enzo Life Science, Farmingdale,
NY, USA), mouse monoclonal heat shock protein 70 (Hsp70, 1:2000, ADI-SPA-810, Enzo Life Science),
mouse monoclonal heat shock protein 60 (Hsp60, 1:1000, D85, Cell Signaling Technology, Danvers, MA,
USA), rabbit monoclonal anti-peIF2α (1:1000, 119A11, Cell Signaling Technologies), rabbit monoclonal
phospho-p44/42 MAPK (Erk1/2; p-ERK, 1:1000, 4370, Cell Signaling Technologies) and rabbit polyclonal
caspase 3 (1:1000, 8G10, Cell Signaling Technologies). Secondary antibodies were HRP-conjugated donkey
anti-rabbit-IgG and sheep anti-mouse-IgG (both from GE Healthcare, Helsinki, Finland). The antibodies
were detected with Enhanced Chemiluminescence kit (Thermo Fischer Scientific).
2.8. Micro Electrode Array (MEA) Electrophysiology
Spontaneously contracting cardiac aggregates were micro-dissected and plated on 0.1% gelatin
coated 6-well micro electrode arrays (MEAs); (MEA1060-Inv-BC, Multichannel Systems, Reutlingen,
Germany). Recordings were performed in serum free embryoid body (EB) medium consisting of
KO-DMEM, nonessential amino acids (Lonza, Basel, Switzerland), GlutaMAX Supplement (Gibco)
and penicillin/streptomycin (Lonza) at 36 ± 1 ◦C (Temperature controller, TC02, Multichannel Systems,
Germany). The MEAs were covered with gas permeable fluorinated ethylene-propylene membranes
(ALA MEA-MEM-sheet, ALA Scientific, Farmingdale, NY, USA) and after a 30 min stabilization period,
the baseline recordings were performed for at least 20 min. Adrenaline (Sigma-Aldrich) was applied
after baseline recording to a final concentration of 100 nM and 1 µM and the effect was recorded at
least for 20 min. Output signals were digitized at 10 kHz by the use of a computer equipped with a
MC-card data acquisition board (Multi Channel Systems, Reutlingen, Germany). MEA data analysis of
the recorded field potential data was analyzed using a custom developed analysis module in Origin
2017 (Microcal OriginTM, Northampton, MA, USA). Beating frequency by beats per minutes (BPM)
and field potential duration (FPD) were extracted from the data (Figure S6). The Bazett’s formula was
used to calculate the beat rate corrected FPD (cFPD). Beat rate variation was determined by measuring
the variation in randomly selected ≥30 consecutive inter-beat intervals calculated by BRV =∑|D n + 1
− D n|/[30 × √2] [31] using a custom built algorithm.
2.9. Hypoxic Stress Induction on MEA
A five-day follow-up experiment was carried out by modifying the oxygen concentration at
regular intervals on the 1-well MEA using a custom built hypoxia chamber [32]. A non-humidified
and filtered, hypoxia gas mixture (1% O2, 5% CO2, 94% N2) or normoxia gas mix (19% O2, 5% CO2,
76% N2) at a flow rate of 5 mL/min (350 mbar pressure) was supplied to the aggregates placed in
serum-free EB formation medium. The measurements were done for five continuous days. On the first
day, the concentration of oxygen in the gas mix was kept at 19% and on day 2, 3 and 4 the aggregates
were subjected to a cycle of hypoxia (1% oxygen) for 3 h and overnight normoxia (19% oxygen).
2.10. Calcium Imaging
Intracellular calcium handling was studied using single wavelength fluorescent Ca2+ dye Fluo-4
AM (acetoxymethyl ester); (Thermo Fisher Scientific) diluted in anhydrous DMSO (Thermo Fisher
Scientific) and imaged with Axio Observer 1A inverted fluorescence microscope (Carl Zeiss CMP
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GmBH, Gottingen, Germany) equipped with an ANDOR iXON3 camera (Andor technology, Belfast,
Ireland). Cardiomyocyte aggregates were dissociated into single CMs onto 0.1% gelatin coated 12 mm
glass coverslips. Four to seven days post-dissociation, CMs were loaded with 4 µM Fluo-4AM in
a HEPES based medium for 30–45 min before imaging. The coverslip was transferred to RC-25
perfusion chamber (Warner Instruments Inc., Hamden, CT, USA) perfused with extracellular solution
and preheated by an SH-27B inline heater (Warner Instruments Ltd.) to 36 ± 1 ◦C. The extracellular
solution consisted of (in mmol/L): 137 NaCl, 5 KCl, 0.44 KH2PO4, 20 HEPES, 4.2 NaHCO3, 5 D-glucose,
2 CaCl2, 1.2 MgCl2 and 1 Na-pyruvate (pH 7.4) and osmolarity at 310 mOsm/KG. The imaging was done
using a 20× objective and FITC filter with the excitation-emission wavelength of 494/506 nm. The imaging
was done for 30–40 seconds captured at a 50 FPS frame rate. Imaging software Zen 2.3 software (Zeiss,
Jena, Germany) was used and the files were acquired in .CZT file format. Mean intensity of the calcium
transients was analyzed by drawing a region of interest (ROI) over the whole cells. The background noise
was subtracted before further processing. The Ca2+ levels are presented as ratiometric values of ∆F/F0.
Recording was done before and 3–5 min after administration of 10 nmol/L adrenaline (Sigma-Aldrich).
The Ca2+ transients were analyzed with Clampfit version 9.2 (Molecular devices, San Jose, CA, USA).
2.11. Teratoma Assay
Approximately 200,000 morphologically intact iPSCs were intratesticularly injected into male
NODSKIDgamma (NSG) mice. The tumours were removed two months after injection, fixed in 4%
paraformaldehyde and embedded in paraffin. Histological sections were cut at 4 µm and stained
with hematoxylin and eosin. Animal care and experiments were approved by the National Animal
Experiment Board in Finland (ESAVI/9978/04.10.07/2014).
3. Results
3.1. Generation and Characterization of hiPSC Lines
Biopsies from two healthy controls and two DCM patients (DCM1 and DCM2) with a heterozygous
p.S143P mutation in LMNA were used to generate hiPSC clones. The basic characterization of one
control line (Control1) has been previously published [22]. Similarly, the other three lines showed
typical characteristics of hiPSC morphology without detectable differences in the expression of
pluripotency markers (Figure S1A,B). A normal karyotype was confirmed in all the lines (data now
shown). The expression of endogenous stem cell markers (REX1, SOX2, NANOG and c-Myc) and the
absence of exogenous transcripts were further confirmed with qRT-PCR in all the lines (Figure S1C,D).
In the teratoma assay, tissues derived from each of the embryonic germ layers (endoderm, mesoderm
and ectoderm) were observed (Figure S1E). Similarly, embryoid body (EB) differentiation confirmed
the expression of three germ layer markers in RT-PCR (Figure S2). The expression of p.S143P mutant
lamin A/C mRNA was detected in DCM-CMs but not in controls (Figure S3). The presence of the
p.S143P (TCC to CCC) mutation in the LMNA was also confirmed in the hiPSC lines derived from
DCM patient1 and 2 by DNA sequencing (Figure S4).
3.2. Characterization of Cardiac Differentiation and Lamina Structure
All hiPSC clones were further differentiated towards cardiac phenotype and analyzed under
normal and hypoxic culture conditions. On an average, 80–98% of cells stained positively with cardiac
specific structural protein, α-actinin, except control2 where only 55% of the cells stained positive
for cardiac marker (data not shown). Based on confocal microscopy analysis, DCM-CMs had more
nucleoplasmic lamin A both under normal culture conditions and after ischemic stress when compared
to controls (p < 0.001 for all, n = 20–30, Figure 1A,B). There were no significant differences in nuclear
size or shape between cell lines under normal culture conditions (Figure 1C and Figure S5). However,
DCM2-CMs showed significantly more deformed nuclei after ischemic stress, as assessed by decreased
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circularity (p < 0.001, n = 20–30, Figure 1C,D). DCM1-CMs, on the other hand, retained their circularity
after hypoxia suggesting that they may be less sensitive to hypoxic conditions.
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0.01 and (***) p < 0.001. (D) Example images of different circularity values corresponding to the 
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Figure 1. Characterization of lamina structure in human induced pluripotent stem cell (hiPSC) derived
cardiomyocytes. (A) Dissociated control and dilated cardiomyopathy (DCM) hiPSC-cardiomyocytes
(CMs) were cultured either in normal culture conditions or exposed to ischemic stress for 3 h, fixed and
stained for lamin A (LA, green), α-actini (magenta) and DNA (DAPI; blue). Representative maximum
projections of Z-stack sections (merged) and single mid-pla e confocal sections (LA, DAPI) from
control1 and DCM2 CMs are shown. Scale b r 10 µm. Fl orescent intensity values are illustrat d below
the image with nucl oplasm/lamina (N/L) ratio numb rs. (B) Fluorescenc intensities at the lamina
region a d in the nucleoplasm were determined from mid-plane confocal sections of 20–30 randomly
selected cells and the average ratios of the signals (nucleoplasm/lamina) were plotted. (***) p < 0.001.
(C) Quantification of nuclear circularity. (**) p < 0.01 and (***) p < 0.001. (D) Example images of different
circularity values corresponding to the calculated average values (Perfect circle = 1.0).
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3.3. DCM-CMs Exhibit Increased Arrhythmias on MEA
Cardiac functional phenotype was confirmed by generation of field potentials at multi-cellular
level on the micro electrode array (MEA). Based on the baseline electrophysiological characteristics,
the DCM-CM aggregates showed a significantly reduced beating rate and a significantly increased field
potential duration compared to the aggregates from controls (Figure 2A,B). To analyze the presence of
functional β-adrenergic receptors, adrenaline was applied on the beating aggregates. β-adrenergic
stimulation with adrenaline showed a positive chronotropic response in all CM aggregates, whereas
the vehicle (distilled water) had no effect on the beating rate (Figure 2C–E).
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electrophysiological characteristics by microelectrode array (MEA) from spontaneously beating 
Figure 2. Functional characterization of hiPSC derived cardiomyocytes. (A) Table shows baseline
electrophysiological characteristics by microelectrode array (MEA) from spontaneously beating
cardiomyocyte clusters. (B) Representative field potential traces from control, DCM1 and DCM2
cardiomyocyte clusters at baseline. (C–E) The bar charts show chronotropic responses of control, DCM1
and DCM2 hiPSC-CM clusters to distilled water used as vehicle (n = 23, 16, 16 respectively); 100 nM
adrenaline (n = 24, 26, 18 respectively) and 1µM adrenaline (n = 18, 16, 13 respectively) with black
and red bars showing the beating frequency at baseline and under vehicle/adrenaline respectively.
Combined results from Control1 and Control2 are shown. Data is presented as mean± s.e.m., (*) p < 0.05,
(**) p < 0.01 and (***) p < 0.001.
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The field potential recordings on MEA revealed that aggregates from DCM-CMs showed increased
arrhythmicity at baseline. The application of adrenaline gave a more pronounced arrhythmic phenotype
with elevated beating irregularity and arrhythmic beats in the DCM-CM aggregates compared to
controls (Figure 3A). Apart from a regular positive chronotropic response (Figure 3B(a)), different
types of arrhythmias were observed, including alternations and irregularity (Figure 3B(b,c)), more
severe arrhythmias similar to the occurrence of a premature beat (Figure 3B(d,e)) and ventricular
tachycardia like arrhythmias (Figure 3B(f,g)). The less severe arrhythmias like alternations and
irregularity were more commonly observed in the controls while more severe arrhythmias were typical
for DCM-CM aggregates.
At baseline the variation in the beating rhythmicity, calculated by short term variation (STV),
was found to be significantly elevated for the inter-beat interval (IBI) and field potential duration (FPD)
in both DCM1-CM and DCM2-CM aggregates compared to controls (Figure 3C(a,d)). Application of
100 nM adrenaline led to a decrease in the STV for IBI and STV for FPD in control and DCM1, but had
no significant effect on DCM2 (Figure 3C(b,e)). Similarly, a higher 1µM concentration of adrenaline
significantly decreased the STV for IBI and STV for FPD in the control CM aggregates while little or no
effect was seen on DCM1 and DCM2 (Figure 3C(c,f)). These results from field potential recordings
suggest that DCM-CMs have increased irregularity at baseline and they are more prone to arrhythmias
on adrenaline application, showing a similarity with ECG findings from patients with DCM due to
LMNA mutation.
3.4. Increased Sarcomere Disorganization after Ischemic Stress in DCM-CMs
In order to test whether a mutation in lamin A/C affects the structural protein organization,
we analyzed the sarcomere length and organization in control and DCM-CMs by confocal microscopy
and automated image analysis fromα-actinin stained cells (Figure 4A). Under normal culture conditions,
there were no significant differences in either sarcomere length or organization between the cell lines
(Figure 4A,B). The stability of sarcomere structure was further tested by exposure to 3 h of ischemic
stress. Interestingly, we observed a dramatic sarcomere disorganization (scattering and loss of
repeatability formed by Z-lines) in the majority of DCM-CMs while the changes were less pronounced
in control CMs (Figure 4A). These differences were also found significant in image analysis carried out
on randomly selected cells (p < 0.05; n = 20 in each group; Figure 4B). Similarly, transmission electron
microscopy analysis showed no difference between control and DCM-CM sarcomere organization at
baseline. However, after ischemic stress, the sarcomeres were notably more scattered in DCM-CMs
relative to controls (Figure 4C).
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16 respectively) and c) 1µM adrenaline (Control, DCM1 and DCM2, n = 23, 24 and 13 respectively).
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3.5. DCM-CMs Show Increased Cellular Stress
To investigate the overall cellular stress in DCM aggregates further, the abundance of various
stress-related markers was studied by western blotting both under normal culture conditions and after
3 h of ischemic stress (Figure 5A). CMs from both DCM1 and DCM2 exhibited clear upregulation of
endoplasmic reticulum (ER) stress marker phosphorylated translation initiation factor 2α (peIF2α) and
heat shock proteins 90, 70 and 60 under normal culture conditions. After 3 h of ischemic stress, peIF2α
and Hsp90, 70 and 60 levels increased in controls and were highly similar to those observed in mutant
cells. In addition, phosphorylated extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) were
significantly upregulated in both DCM-CM under normal culture conditions indicating activation of
mitogen-activated protein kinase (MAPK) and a similarity with previously reported LmnaH222P/H22P
DCM mouse model [16].
Confocal microscopy analysis revealed that the hypoxia inducible factor 1α (Hif-1α) was
significantly more upregulated in DCM than in control cells after 3 h of ischemic stress (p < 0,001; n > 15,
Figure 5B). More specifically, Hif-1α level increased exponentially after 2 h of hypoxia, reached its peak
value at 3 h and decreased substantially thereafter while in control cells only moderate accumulation
was observed after 4 h hypoxia (p < 0,05; n > 20, Figure 5C).
Finally, we wanted to test whether increased cellular stress would have any effect on DNA damage
and cell viability. The number of cells positive for phosphorylated histone H2AX (γH2AX), a marker
for double-strand DNA breaks, was significantly increased in DCM cells compared to control under
normal culture condition (p < 0.05; n = 500; Figure 5D,E). However, no significant difference was found
after ischemic stress as virtually all the DCM and control cells stained positively (data not shown).
Based on the increased levels of cleaved (active) caspase-3, there also appeared to be the induction
of apoptotic cell death among DCM1 and DCM2 CMs already under normal culture conditions and
more distinctly after ischemic stress while such cleavage was not detected in control CMs (Figure 5A).
In summary, these findings suggest that DCM-CMs exhibit elevated baseline cellular stress that may
sensitize to programed cell death upon additional physiological stress.
3.6. Hypoxia Reduces Beat Rate of Cardiac Aggregates
To test whether hypoxia induced stress response has any effect on the function of hiPSC-CMs,
cardiac aggregates on MEA were exposed to repeated cycles of hypoxia (1%, 3 h) on three consecutive
days, followed by overnight recovery in normoxia. Hypoxia stress induction assay by a custom built
hypoxia chamber on the MEA was used for this recording (Figure S7). The main observation was that
hypoxia reduced the beating rate in all the hiPSC-CM aggregates (Figure 5F). However, the second and
third hypoxia cycle had an exaggerated effect on DCM1 and DCM2 aggregates, with DCM2 having
significantly reduced beat rate at second and third hypoxia cycle (Figure 5F). Interestingly, overnight
recovery in normoxia almost completely restored the functionality in controls but little or no effect was
observed on DCM1 and DCM2 aggregates (n = 10 control, n = 5 DCM1, n = 11 DCM2). After three
hypoxia–normoxia cycles on day 5, the beating rate in controls was about 80% of the original beating
rate, while it was between 30–45% in DCM aggregates indicating an increased sensitivity to hypoxia
induced stress (Figure 5F).
3.7. DCM-CMs Show Impaired Calcium Dynamics
To understand the functionality and calcium handling characteristics, single dissociated hiPSC-CMs
were studied using Ca2+ imaging. A representative calcium transient with measured parameters is
shown in Figure 6A. The basal calcium transient characteristics of DCM-CMs showed a significantly
reduced beating rate and increased calcium transient peak duration when compared to control
(Figure 6B). These results are consistent with results from cardiac aggregates on MEA displaying
decreased beating rate (Figure 2A). At baseline the Ca2+ levels calculated by ∆F/F0, calcium transient
decay tau, rise time and decay time were also elevated in DCM-CMs compared to controls (Figure 6C).
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The fluorescence intensities of Hif-1α were determined from all the confocal sections of >15 randomly 
selected cells at different time points and the average normalized signals were plotted. (D) Control1 
and DCM2 hiPSC-CMs were cultured under normal culture conditions, fixed and stained for γH2AX, 
cTnT and DNA (DAPI). (E) γH2AX positive cells from control1 and DCM2 were counted and plotted 
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Figure 5. DCM hiPSC-CMs show increased elevated cellular stress. (A) Western blot analysis of lamin
A/C, phospho-eIF2α (peIF2α), Hsp90, Hsp70, Hsp60, phospho-ERK1/2 (pERK1/2) and cleaved caspase-3
under normal culture conditions and after exposure to ischemic stress for 3 h. Actin was used as a
loadi g control. The average num rical values of signal intensities r lative to the loading control (actin)
are shown b low each blot. n = 2 individual experiments. Control2 hiPSC-CMs were not qu lified
for analysis due to lower differentiation efficiency compared to ot er lines. (B) Confocal microscopy
analysis of Hif-1α intensity. C ntrol1, DCM1 and DCM2 hiPSC-CMs were cultured either in normal
culture conditions or exposed to ischemic stress for 2 h, 3 h, 4 h a d 5 h, fixed and stained for Hif-1α,
cardiac marker cTnT and DNA (DAPI). A 3 h time point is shown. Scale bar 20 µm. (C) The fluorescence
intensities of Hif-1α were determined from all the confocal sections of >15 randomly selected cells
at different time points and the average normalized signals were plotted. (D) Control1 and DCM2
hiPSC-CMs were cultured under normal culture conditions, fixed and stained for γH2AX, cTnT and
DNA (DAPI). (E) γH2AX positive cells from control1 and DCM2 were counted and plotted (n = 500).
(F) Effect of three repeated 3 h cycles of hypoxia (1% O2) shown as H1, H2 and H3 and overnight
re-oxygenation (19% O2) on beat rate of hiPSC-CMs recorded on MEA. Control data presented in F
is combined from Control1 and 2. Data is expressed as mean ± s.e.m., (*) p < 0.05, (**) p < 0.01 and
(***) p < 0.001.
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Figure 6. Analysis of intracellular calcium dynamics by calcium (Ca2+) imaging in hiPSC-CMs.
(A) Measurement of Ca2+ transient parameters ∆F/F0, peak duration, rise time, decay time and decay
tau for the calcium imaging data. (B) Ca2+ transient characteristics recorded from hiPSC-CMs at
baseline. (C) Calcium imaging parameters for control, DCM1 and DCM2 CMs at baseline are shown as
∆F/F0 (n = 34, 40 and 42 respectively), decay tau (n = 31, 41 and 41 respectively), rise time (n = 32, 39
and 40 respectively) and decay time (n = 31, 34 and 35 respectively). (D) Calcium imaging parameters
at baseline (BL) and in the presence of 10 nM adrenaline. (E) Representative regular (a) and arrhythmic
Ca2+ transients (b–f) detected under baseline or under 10 nM adrenaline in control, DCM1 and DCM2
CMs. Dysrhythmia (b) and alternations (c) were categorized as minor arrhythmias and oscillations (d),
extra peaks (e) and plateau abnormalities (f) as major arrhythmias. The red arrows represent the Ca2+
abnormalities. (F) Frequency of major arrhythmias in control, DCM1 and DCM2 single dissociated
hiPSC-CMs at baseline (BL) and under 10 nM adrenaline (Adr). Data is presented as mean ± s.e.m
and ANOVA or non-parametric pair test was used for statistical analysis. (*) p < 0.05, (**) p < 0.01 and
(***) p < 0.001. Control data presented here is combined from Control1 and Control2.
To test the effect of adrenergic stress, the calcium transient characteristics were determined under
10 nM adrenaline. Adrenaline increased the mean beat rate (BPM) significantly in all the lines and
reduced the mean calcium transient peak duration in control and DCM1 significantly while only a
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similar trend was seen in DCM2 (Figure 6D). The calcium levels by ∆F/F0 and decay time also reduced
in all cell lines, but this did not reach statistical significance. The decay tau decreased and rise time
increased significantly in controls but neither of these were found significantly altered in DCM-CMs
(Figure 6D).
Apart from the regular calcium transients (Figure 6E(a)), different arrhythmias were observed
on calcium transients comprising of irregular beating and alternations (Figure 6E(b,c)) as well as
more severe arrhythmias including oscillation, extra peaks and plateau abnormalities (Figure 6E(d–f)).
Increased frequency of major arrhythmias was observed in DCM-CMs already at baseline (Figure 6F)
and β-adrenergic stimulation seemed to increase their occurrence. However, no clear effect was
observed in control CMs upon adrenaline treatment (Figure 6F).
4. Discussion
In this work, we have generated and characterized a novel hiPSC-CM model carrying the p.S143P
LMNA mutation.
Structural analysis showed that the sarcomeres were highly organized in DCM-CMs and were
indistinguishable from control-CMs. However, after ischemic stress α-actinin staining demonstrated
significantly more disrupted sarcomere organization in DCM-CMs (Figure 4). Previously, a similarly
disrupted sarcomere organization was observed in CMs carrying the LMNA p.R190W mutation but
these differences were detectable already under normal culture conditions [33]. These phenotypic
cellular differences between lamin mutations may be due to differences in pathogenicity and assembly
properties of mutant lamin protein as they may have different effects e.g., on the organization of LINC
(linker of nucleoskeleton and cytoskeleton) complexes.
Similar to our earlier observations on p.S143P mutant primary fibroblast [25], DCM-CMs had
significantly more nucleoplasmic lamin A/C relative to controls (Figure 1A,B). Since p.S143P lamin
A/C is incapable of forming regular lamin filaments in vitro [25] and the wild type and mutant allele
were transcribed in an equal manner (Figure S3), it is plausible that the excess nucleoplasmic lamin
pool is formed by the mutant protein. Vice versa, such mislocalization shall lead to reduced amounts
of lamin A/C at the lamina region, as pointed out by our analysis (Figure 1B). Furthermore, this may
influence lamina stability and lead to deformed nuclei under stressed conditions as observed in the
circularity analysis of DCM2-CMs (Figure 1C,D). In summary, these results indicate that while control
CMs are capable of adapting to stress by keeping their lamina intact, the LMNA-mutant DCM-CMs
are more sensitive due to insufficient amounts of lamin A/C (i.e., haploinsufficiency) and potentially
fragile lamina. This may eventually cause DNA damage and cell death especially in tissues that are
exposed to constant stress, such as in the cardiac muscle. The latter is also supported by increased
γH2AX staining (Figure 5D,E) and caspase-3 activity (Figure 5A) in DCM-CMs upon hypoxia.
Immunoblotting revealed significant upregulation of several stress related signaling proteins such
as Hsp90, Hsp70 and Hsp60 in DCM-CMs under normal culture conditions (Figure 5A). Hsp70 and
Hsp90 protein family members are essential chaperones in cardiomyocytes and they have a critical role
in maintaining cardiac function during stress. Hsp70 (Hsp72 isoform) is only expressed under stress
to support correct protein folding and to deliver proteins for proteosomal degradation [34]. Studies
on Hsp70 and heart failure have shown conflicting results. Some studies have reported increased
Hsp70 mRNA or protein levels among DCM patients [35,36] while this has not been validated by
others [37,38]. Nevertheless, accumulating data suggests that Hsp70 plays an essential role in many
signaling pathways related to myocardial ischemia/reperfusion (I/R) injury, oxidative stress, Ca2+
overload and apoptosis. Chaperone Hsp90 is involved in many cellular processes including protein
folding, protein degradation and signal transduction [39] and may also have a cardioprotective role in
I/R injury [34,40,41]. Similarly, Hsp60 is upregulated among DCM patients [38,42] but may have both
pro- and anti-apoptotic roles depending on cell type [39]. Therefore, constant upregulation of Hsp
family members may have both beneficial and deleterious effects on lamin mutant CMs.
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Our previous study showed that endogenous and ectopic expression of p.S143P lamin A leads to
hyperphosphorylation of eIF2α in fibroblasts [25]. Similarly, elevated levels of peIF2α were detected
in DCM-CMs but not in control CMs under normal culture conditions (Figure 5A). Typically eIF2α
is phosphorylated upon activation of unfolded protein response (UPR) or ER stress, caused by an
accumulation of unfolded or misfolded proteins in the ER. The UPR and ER stress have been linked
with the pathophysiology of heart failure and this may be one of the cellular mechanisms that trigger
and promote cardiomyocyte apoptosis in failing human hearts [43]. Meanwhile, Hsp70 and Hsp90
bind and stabilize ER-stress sensor proteins, such as PERK and IRE1α, to enhance adaptation to
ER-stress and inhibit apoptosis [44,45]. It is currently unclear whether expression of mutant lamin
A/C directly or indirectly triggers UPR (e.g., due to misfolding) and whether targeting these complex
signaling mechanism would improve CM functionality. However, in patient fibroblasts treatment with
chaperone 4-phenylbutyric acid inhibited aggregation of mutant lamin and improved viability [25],
which supports testing similar drugs on DCM-CMs in the future. We also observed significant
upregulation of pERK1/2 in both DCM-CM lines under normal culture conditions. This result correlates
with previous data from the LmnaH222P/H22P mouse model [16] and further supports the involvement
of MAPK pathway in the pathobiology of LMNA-related DCM.
Reduction of oxygen forces the cardiomyocytes to switch from aerobic to anaerobic respiration
pathways, leading to an increase in glycolytic substrates like lactate [46,47] while perturbation on
ATP generation affects cardiac contractility [48]. In our study, repeated hypoxia and normoxia cycles
mimicking I/R injury reduced the beating in all aggregates but had more severe effects on DCM-CMs
with only 30–45% recovery of their original beat rate (compared to 80% in controls, Figure 5F).
Increasingly compromised sarcomere structure due to hypoxic insults, as well as increased DNA
damage and constant upregulation of stress proteins such as Hif1α and HSP70 [46] thus could explain
the low recovery of the beat rate in DCM-aggregates and the initiation of arrhythmias on multicellular
and single CM level. This experiment further demonstrates the feasibility of hiPSC-CMs for cardiac
disease and I/R injury modeling to advance our understanding on cardiac pathophysiology.
Ca2+ imaging studies revealed elevated cytosolic calcium levels and increased decay tau, rise time
and decay time in DCM-CMs compared to controls. Similarly Nikolova et al. reported significantly
increased time to 50% relaxation of the Ca2+ transient in LMNA+/− and LMNA−/− mice’ CMs [17].
However, no difference in baseline Ca2+ levels and rise time were observed whereas we found these to
be increased in DCM-CMs. Our results are also in line with Ca2+ transient data from failing human
hearts, where increased time of calcium decay, slow rates of recovery and increased intracellular
Ca2+ levels have been reported [49]. The rise time of the calcium transient is due to released calcium
from the intracellular calcium stores through RYR2 channels, the decay phase is due to removal of
Ca2+ via SERCA and Na+/Ca2+ exchanger (NCX) and any of these pathways could be affected in
the DCM-CMs [50]. Since ER is also involved in maintaining intracellular Ca2+ homeostasis and
development of cardiac conductive system [51] and prolonged ER stress has been linked to many
pathological cardiovascular diseases [52], further studies are needed to understand the exact links
between these mechanisms in lamin mutant CMs.
MEA recordings revealed a reduced beating rate and increased field potential durations in
DCM-CM aggregates compared to controls. Similarly, ventricular CMs from LmnaN195K/N195K
mutant mice showed significantly reduced beating rates, significantly prolonged APD50 and APD90
and occurrence of EADs (early afterdepolarization) and DADs (delayed afterdepolarization) on
stimulation [53]. During β-adrenergic stimulation, increased Ca2+ load beyond the sarcoplasmic
reticulum threshold may lead to pronged action potentials, varying spontaneous calcium release,
increased beat rate variation and arrhythmias [49,54,55]. In our Ca2+ imaging studies, β-adrenergic
stimulation clearly increased arrhythmias in DCM-CMs but had no significant effect on control-CMs
(Figure 6). In analogue, increased premature beats and VT-type arrhythmias were observed in
DCM-aggregates on MEA when compared to controls (Figure 3). A similar intracellular calcium
overload and increased sensitivity to chronotropic stress by norepinephrine was reported in an earlier
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iPSC-CM model of familial DCM from a RBM20 mutation [56]. This is of particular interest as reduced
RBM20 levels have also been reported in Lmna-mutant cells with DCM-related mutations [57]. In our
study, single DCM-CMs were more arrhythmic compared to cell clusters on MEA, most likely due to a
lack of cell–cell connections [58]. Our results are also in line with previous studies where β-adrenergic
stimulation increased the SR calcium load and caused spontaneous calcium release and arrhythmias in
rabbit hearts and in a rabbit heart failure model [59,60].
Atrial fibrillation, AV-block, ventricular arrhythmias and non-sustained ventricular tachycardia
are frequent even among asymptomatic LMNA mutations carriers [61]. Furthermore, case studies
have reported increased and more severe arrhythmias in individual patients following physical
exercise [62]. At the cellular level, dysrhythmias were quantified by STVs, which were found to be
increased in DCM-CM clusters (Figure 3C). The detailed mechanisms of increase in beating rhythm
variability at the cellular level remains incompletely understood, but studies point towards irregularity
in spontaneous calcium release, calcium regulation and repolarization time [31,54,63]. A previous
study on hESC-CM reported that disturbed intra-cellular Ca2+ handling increased variation in the beat
rate [64]. Significantly increased beat rate variation has also been reported in animal models and in
selected human subjects prior to the onset of major arrhythmias [54]. Actually the SVT has consistently
been demonstrated to be a more reliable indicator of arrhythmogenic risk than prolonged ventricular
repolarization [31,54]. This could explain the increased arrhythmias in DCM-CM aggregates showing
increased field potential duration and increased STV in the current study.
5. Conclusions
This is the first hiPSC-CM model for p.S143P LMNA mutation, a founder mutation affecting
several families in Finland. The mutation-specific DCM-CMs demonstrated bradyarrhythmia and
severe arrhythmic beats both at the aggregate and single-cell level. The manifestation of the DCM
phenotype was supported by data from MEA, Ca2+ imaging, western blot and confocal imaging
experiments with increased beat rate variability, abnormal calcium handling, increased sensitivity to
stress and elevated expression of stress proteins. The hiPSC-CMs further showed an altered lamina
structure and increased disorganization of sarcomere structure upon hypoxic stress. This model helps
to understand the molecular pathology of LMNA-related DCM and provides a platform for drug
testing in the future.
5.1. Clinical Significance
Currently there are no specific medications for individuals carrying DCM-related LMNA mutations
to prevent the onset of the disease or for those already having the clinical phenotype. Better knowledge
of the disease pathophysiology would enable to design new treatments in a more focused manner and
mutation and disease-specific CMs provide a powerful platform for this aim.
5.2. Study Limitations
Although hiPSC-CMs present an advantage over existing animal models and expression systems,
hiPSC-CMs present batch wise variations in reprogramming and differentiation. The hiPSC-CM also
have an immature phenotype compared to adult human cardiomyocytes. Hence care must be taken
while extrapolating to clinical data. Investigating the mechanism of beat rate variation, arrhythmia
and hypoxia was beyond the scope of this study. Isogenic controls would be ideal but unfortunately
they were not available for the current study.
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Area, Figure S6. Representative field potential trace, Figure S7. The set-up of custom-made hypoxia chamber.
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